Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atebimetinib - Immuneering

Next Previous
Drug Profile

Atebimetinib - Immuneering

Alternative Names: IMM-1-104

Latest Information Update: 16 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immuneering
  • Class Amines; Aniline compounds; Antineoplastics; Chromones; Coumarins; Fluorobenzenes; Phenylcarbamates; Small molecules; Sulfonamides
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma
  • Phase I/II Solid tumours

Most Recent Events

  • 10 Sep 2026 Efficacy data from a phase III trial in Adenocarcinoma released by Immuneering
  • 21 Jul 2026 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical studies in Solid tumours released by Immuneering
  • 05 Jun 2026 Immuneering Corporation initiates enrolment in a phase-III trial for Adenocarcinoma (Combination therapy, First-line therapy, Metastatic disease) in USA (PO) (NCT07562152)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top